Literature DB >> 8800450

Uptake and washout of I-123-MIBG in neuronal and non-neuronal sites in rat hearts: relationship to renal clearance.

A S Arbab1, K Koizumi, T Araki.   

Abstract

We investigated the uptake and washout of I-123-metaiodobenzylguanidine (MIBG) in neuronal (both intra- and extravesicular) and non-neuronal sites in the heart and its relationship to renal clearance. Acute renal failure was induced in rats by ligating the renal vessels, and the findings were compared with those of sham-operated rats. Each group consisted of control, reserpine-treated and 6-hydroxydopamine (6-OHDA)-treated subgroups. Rats were sacrificed at 10 minutes and 4 hours after injection of MIBG. MIBG activity was calculated in specimens of heart, spleen, lung and blood. At 10 minutes, no significant difference in MIBG uptake in the heart was observed among the subgroups or between sham-operated and renal failure rats despite a significantly higher blood MIBG activity in the latter. At 4 hours, however, the hearts of both reserpine-treated and 6-OHDA-treated rats showed significantly lower MIBG uptake than control rats. Furthermore, the hearts of renal failure rats showed higher MIBG uptake in the control and reserpine-treated rats than in the corresponding subgroups in sham-operated rats. Intra and extravesicular neuronal uptake of MIBG in the heart were estimated using control, reserpine-treated and 6-OHDA-treated rats. Vesicular uptake values were similar in both the sham-operated group (0.51% ID/g) and the renal failure group (0.44% ID/g). But extravesicular neuronal uptake values were quite different in the renal failure group (0.86% ID/g) and the sham-operated group (0.19% ID/g). In conclusion, uptake to and washout from extravesicular neuronal sites may depend on the concentration of MIBG in the blood or the state of renal clearance, but vesicular uptake may be independent of these factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800450     DOI: 10.1007/bf03165394

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  30 in total

1.  Studies on the mechanisms of 6-hydroxydopamine cytotoxicity.

Authors:  G Jonsson
Journal:  Med Biol       Date:  1976-12

2.  Neuronal uptake and metabolism of 2- and 6-fluorodopamine: false neurotransmitters for positron emission tomographic imaging of sympathetically innervated tissues.

Authors:  G Eisenhofer; D Hovevey-Sion; I J Kopin; R Miletich; K L Kirk; R Finn; D S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

3.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

4.  Myocardial imaging with a radioiodinated norepinephrine storage analog.

Authors:  D M Wieland; L E Brown; W L Rogers; K C Worthington; J L Wu; N H Clinthorne; C A Otto; D P Swanson; W H Beierwaltes
Journal:  J Nucl Med       Date:  1981-01       Impact factor: 10.057

5.  Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.

Authors:  J C Sisson; B Shapiro; L Meyers; S Mallette; T J Mangner; D M Wieland; J V Glowniak; P Sherman; W H Beierwaltes
Journal:  J Nucl Med       Date:  1987-10       Impact factor: 10.057

6.  Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy.

Authors:  J S Gill; G J Hunter; G Gane; A J Camm
Journal:  Am Heart J       Date:  1993-08       Impact factor: 4.749

7.  Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma.

Authors:  T J Mangner; M C Tobes; D W Wieland; J C Sisson; B Shapiro
Journal:  J Nucl Med       Date:  1986-01       Impact factor: 10.057

8.  Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart.

Authors:  M Nakajo; K Shimabukuro; H Yoshimura; R Yonekura; Y Nakabeppu; P Tanoue; S Shinohara
Journal:  J Nucl Med       Date:  1986-01       Impact factor: 10.057

9.  The effects of intraperitoneal injection of 6-hydroxydopamine on the turnover and the levels of the brain catecholamines and the levels of plasma corticosterone in rats.

Authors:  A Kawa; T Kamisaki; T Ariyama; T Kawabata; Y Maeda; O Okamoto; T Kanehisa
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 Mar-Apr       Impact factor: 2.557

10.  Decrease in adrenaline content of various organs of the rat after 6-hydroxydopamine.

Authors:  A Sudo
Journal:  Eur J Pharmacol       Date:  1985-08-07       Impact factor: 4.432

View more
  4 in total

Review 1.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

2.  Cardiac sympathetic denervation in 6-OHDA-treated nonhuman primates.

Authors:  Valerie Joers; Kristine Dilley; Shahrose Rahman; Corinne Jones; Jeanette Shultz; Heather Simmons; Marina E Emborg
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

3.  The role of adrenergic and muscarinic receptors in stress-induced cardiac injury.

Authors:  Boris K Kurbatov; Ekaterina S Prokudina; Leonid N Maslov; Natalia V Naryzhnaya; Sergey V Logvinov; Alexander S Gorbunov; Alexandr V Mukhomedzyanov; Andrey V Krylatov; Nikita S Voronkov; Andrey S Sementsov; Konstantin V Zavadovsky; Viktor V Saushkin; Rajendra P Nagarajan; Peter R Oeltgen
Journal:  Pflugers Arch       Date:  2021-07-10       Impact factor: 3.657

Review 4.  Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence.

Authors:  Lorena Cuenca-Bermejo; Pilar Almela; Javier Navarro-Zaragoza; Emiliano Fernández Villalba; Ana-María González-Cuello; María-Luisa Laorden; María-Trinidad Herrero
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.